Early Phase 1 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 6 and 17 years old (inclusive) and have been diagnosed with Stargardt disease
- You have a specific gene change (at least one ABCA4 gene variant on each chromosome) linked to Stargardt disease
- Both of your eyes have clearly visible areas of damage in the central part of the retina (the macula) that are consistent with Stargardt disease
- Your vision meets certain requirements measured using a specific eye chart called the ETDRS letter chart
- You are willing to use contraception throughout the study
- Your blood tests, urine tests, and eye examinations meet the standards required by the trial
Who may not be able to join:
- You currently have, or have a history of, inflammation or swelling inside either eye (called uveitis)
- You have had an infection in or around either eye within the past 2 weeks
- You have, or have had, a condition affecting the clear front surface of the eye (corneal dystrophy) in the eye being studied
- You have a history of HIV or hepatitis A, B, or C infection
- You have previously received any gene therapy or cell therapy treatment (such as a stem cell transplant)
- You have had eye surgery in the study eye within the past 3 months
- You have taken part in another clinical trial testing an oral (taken by mouth) treatment for Stargardt disease within the past 3 months, or within 5 half-lives of the last dose you received
- You are currently taking any other treatment that the trial doctor believes could interfere with the eye procedure or the healing process
- You have any other condition that the trial doctor believes would prevent you from completing all follow-up visits or make participation unsuitable for you (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, HuidaGene Therapeutics Co., Ltd.
Phone: +86 021-25076143
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of systemic adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.